Physician profile
Christopher J Bartolone
NPI 1548246788
$3,442.56
in general payments reported to CMS, 2019-2025
22 companies · $640 in 2025
The $640 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $44.05 · 2021: $233 · 2022: $799 · 2023: $467 · 2024: $610 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.45 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $776.70 | 2019-2025 | Stelara, Tremfya |
| Cook Medical LLC | $358.29 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.64 | 2019-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $169.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.75 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Allergan, INC. | $52.26 | 2019-2020 | |
| Lilly USA, LLC | $46.40 | 2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $42.40 | 2019-2022 | |
| Exact Sciences Corporation | $40.80 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Qol Medical, LLC | $31.85 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $30.29 | 2023 | Dupixent |
| Madrigal Pharmaceuticals | $19.94 | 2025 | Rezdiffra |
| Sandoz INC. | $19.90 | 2024 | Hyrimoz |
| Ucb, INC. | $19.62 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.53 | 2025 | |
| Merck Sharp & Dohme LLC | $18.60 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $18.03 | 2025 | Vowst |
| Celgene Corporation | $17.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.68 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2024 | Simlandi |
| Intercept Pharmaceuticals, INC. | $14.38 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bartolone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.